

#### ANALYZED BY:

Anresco Laboratories 1375 Van Dyke Avenue, San Francisco, CA 94124 C8-0000052-LIC



#### DISTRIBUTOR:

Metta Medical

C11-0001250-LIC

Matrix

Overall:

#### **CULTIVATOR / MANUFACTURER:**

Metta Medical



CDPH-10004472

Date Reported:

#### SAMPLE INFORMATION

Sample No.:

Level - Lights Out Protab+ -PT220620LO **Product Name:** 

Concentrate (Orally Consumed Concentrate)

**Pass** 

Batch #: PT220620LO Product-Batch Size (Units): 9994

Source UID: 1A4060300020081000001334

Sample Increments: 20 Sample Weight / Increment (g): 1.64 Total Sample Weight (g): Date Collected: 32.8 06/21/2022 06/22/2022 Date Received:

06/24/2022

06/24/2022

#### **TEST SUMMARY**

**Pass** Pass **Cannabinoid Profile:** Microbiological Screen: Pesticide Residue Screen: Residual Solvent Screen: **Pass** Pass **Pass Heavy Metal Screen:** Foreign Material: Pass Pass Mycotoxin Screen: Water Activity:

#### Cannabinoid Profile Pass

Method:

MF-CHEM-15

Instrument: Liquid Chromatography Diode Array Detector (LC-DAD)

**Limit of Detection** Limit of Quantification 0.4 mg/g

Cannabinoid	mg/g	%	mg/serving	mg/package	Status
Δ8-THC	30.24	3.024	5.03	50 27	-
Δ9-THC	111 88	11.188	18.59	185.94	Pass
Δ9-THCA	9.49	0.949	1 58	15.76	-
THCV	0.92	0.092	0.15	1 54	-
THCVA	ND	ND	ND	ND	-
CBD	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td></loq<>	-
CBDA	ND	ND	ND	ND	-
CBC	2.42	0.242	0.40	4.03	-
CBCA	ND	ND	ND	ND	-
CBDV	ND	ND	ND	ND	-
CBG	12.10	1.210	2.01	20.10	-
CBGA	ND	ND	ND	ND	-
CBN	28.29	2.829	4.70	47.02	-
Total THC	120 20	12.020	19.98	199.77	-
Total CBD	ND	ND	ND	ND	-
Total Cannabinoids	195 34	19 534	32.47	324,66	-
Sum of Cannabinoids	194.18	19,418	32.27	322.72	-
Serving Weight (g)	0.1662				
Package Weight (g)	1,66				

### Microbiological Screen Pass



06/24/2022

Analyte	Method	Findings	Status
Salmonella	AOAC 2016.01	Negative/1g	Pass
STEC	3M MDS STEC/FAF	Negative/1g	Pass

### Pesticide Residue Screen Pass

06/24/2022

MF-CHEM-13 Method:

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.02/0.06	ND	5.0	Pass

Sample #: 1130723

Batch #: PT220620LO

Anresco Laboratories www anresco.com

1375 Van Dyke Ave, San Francisco, CA 94124

Page 1 of 4

Report ID: S-2

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.



Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Aldicarb	0.02/0.06	ND ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0 2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.02/0.06	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.08	ND	0.02	Pass
	0.02/0.06	ND	0.02	Pass
Chlorpyrifos Clofentezine	0.02/0.06	ND ND	0.5	Pass
		ND	0.02	Pass
Coumaphos	0.02/0.06	ND ND		
Cyfluthrin	0.10/0 30		1.0	Pass
Cypermethrin	0.10/0 30	ND	1.0	Pass
Daminozide	0.02/0.06	ND	0.02	Pass
DDVP (Dichlorvos)	0.02/0.06	ND	0.02	Pass
Diazinon	0.02/0.06	ND	0.2	Pass
Dimethoate	0.02/0.06	ND	0.02	Pass
Dimethomorph	0.02/0.06	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.02/0.06	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.02/0.06	ND	5.0	Pass
Metalaxyl	0.02/0.06	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.02/0.06	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.02/0.06	ND	0.5	Pass
Oxamyl	0.02/0.06	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.04/0.10	ND	0.2	Pass
Permethrins	0.10/0 30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.02/0.06	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.02/0.06	ND	0.02	Pass
Pyrethrins	0.10/0 30	ND	1.0	Pass
Pyridaben	0.02/0.06	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.02/0.06	ND	0.02	Pass
Tebuconazole	0.02/0.06	ND ND	2.0	Pass
		ND ND	0.02	
Thiadoprid	0.02/0.06			Pass
Thiamethoxam	0.02/0.06	ND ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Residual Solvent Screen Pass

06/24/2022

USP OVI<467>

Instrument: Gas Chromatography Mass Spectrometry (GC/MS)

Analyte	LOD/LOQ(ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0 2/0.5	ND	1	Pass

Sample #: 1130723 Batch #: PT220620LO

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124 Page 2 of 4

Report ID: S-2

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure  $under applicable \ law. \ If you \ have \ received \ this \ document \ in \ error, \ please \ immediately \ notify \ us \ and \ return \ it \ to \ the \ address \ listed \ above.$ 



Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Acetone	67/200	ND	5000	Pass
Acetonitrile	67/200	ND	410	Pass
Benzene	0 2/0.5	ND	1	Pass
n-Butane	67/200	ND	5000	Pass
Chloroform	0 2/0.5	ND	1	Pass
Ethanol	67/200	ND	5000	Pass
Ethyl acetate	67/200	ND	5000	Pass
Ethyl ether	67/200	ND	5000	Pass
Ethylene oxide	0 2/0.5	ND	1	Pass
n-Heptane	67/200	ND	5000	Pass
n-Hexane	67/200	ND	290	Pass
Isopropyl alcohol	67/200	ND	5000	Pass
Methanol	67/200	ND	3000	Pass
Methylene chloride	0 2/0.5	ND	1	Pass
n-Pentane	67/200	ND	5000	Pass
Propane	67/200	ND	5000	Pass
Toluene	67/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	67/200	ND	2170	Pass
Trichloroethylene	0 2/0.5	ND	1	Pass

**Heavy Metal Screen** Pass

06/24/2022

MF-CHEM-16 Method:

Instrument: Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.05	ND	0.5	Pass

Foreign Material Pass

06/24/2022

Method: MF-MACRO-5

Analyte	Findings	Limit	Status	
Sand, Soils, Cinders, and Dirt	ND	25%	Pass	
Mold	ND	25%	Pass	
Imbedded Foreign Material	ND	25%	Pass	
Insect Fragment	ND	1 per 3g	Pass	
Hair	ND	1 per 3g	Pass	
Mammalian Excreta	ND	1 ner 3g	Pass	

Mycotoxin Screen Pass



06/24/2022

MF-CHEM-13

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Analyte	LOD/LOQ (µg/kg)	Findings (µg/kg)	Limit (µg/kg)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/20	ND	20	Pass

06/23/2022 **Water Activity** 

MF 14G051 Method: Instrument: Decagon

Analyte	Findings	Limit	Status
Water Activity	0 38	0 85	Pass

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124

Sample #: 1130723 Batch #: PT220620LO Page 3 of 4

Report ID: S-2



Total THC = Δ9-THC + (0.877 \* Δ9-THCA) Total CBD = CBD + (0877 \* CBDA)

( ) = Not Tested, ND = None Detected, <LOQ = Below Limit of Quantitation, LOD = Limit of Detection

Total Cannabinoids =  $\Sigma$  (neutral cannabinoids) + [0.877 \*  $\Sigma$  (acidic cannabinoids)]

All LQC samples were performed and met the acceptance criteria in CCR Title 4 Division 19. Chapter 6. Article 7. §15730. pursuant to §15726.(e)(13).

Lab Co Director

June 24, 2022

